Alzheimers: two U.S. laboratories stopped testing a new medicine

| |

alzheimers-diseaseAug 8, New Delhi: The American pharmaceutical companies Pfizer and Johnson & Johnson announced Monday night stop trials in phase 3 (final) of a new medicine supposed to fight Alzheimer’s disease.

Pfizer and Janssen Alzheimer Immunotherapy, a subsidiary of Johnson & Johnson, said that tests of the molecule “bapineuzumab” in patients with mild to moderate Alzheimer’s disease had not produced the hoped-for improvements cognitive or functional.

This is the second time in less than a month that these laboratories announced a disappointment for this molecule.

On July 23 they had indicated that clinical objectives were not achieved during a phase 3 clinical trial in patients with the ApoE4 gene, which increases the chances of having the disease, while indicating that the tests continued on patients and non-carriers of the ApoE4 gene, the U.S. and Europe for Janssen for Pfizer.

This time laboratories announced that “the clinical development in phase 3 intravenous bapineuzumab is arrested for Alzheimer’s disease with mild to moderate”.

Johnson & Johnson said that this would lead to the failure to get a load of 300 to 400 million in its third quarter results.

The bapineuzumab is an antibody targeting the protein beta-amyloid, which has a toxic effect on the brain and is considered central to Alzheimer’s disease.

“We are disappointed with the results of two studies on bapineuzumab intravenously, especially given the urgent need for advances against Alzheimer’s disease, but we believe that target beta-amyloid is a promising way to find potential clinical benefits for people who suffer from this disease, “argued Husseini Manji, head of neuroscience therapies Janssen Research.

“Studies with other molecules that are at a less advanced stage of development is ongoing and future development strategies will be discussed” with partners in the laboratory, he added.

On his side a head of research at Pfizer, Steven Romano, quoted in a separate statement, noted that the data collected during these tests would “advance the understanding of this complex disease and to advance research in this area” .

Some 35.6 million people had dementia, including Alzheimer’s disease, in 2010, according to one estimate cited by Pfizer, a total cost of over $ 600 billion.

The number of patients “will almost double every 20 years to wait 65.7 million in 2030 and 115.4 million in 2050”, note again the laboratory.

News Gathered by India News

Posted by on Wednesday, August 8th, 2012. Filed under Health, Life Style. You can follow any responses to this entry through the RSS 2.0. You can skip to the end and leave a response. Pinging is currently not allowed.

Leave a Reply